Search research articles
Contact Us
Filters
Showing results (81-90 of 216) with videos related to
Page
of 22
Sort By:
Research and Practice in Thrombosis and Haemostasis
|
February 18, 2026
Factor VIII <i>in vitro</i> bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays
Jacob Lund, Mirella Ezban, Kasper Jensen, et al.
Blood
|
April 23, 2017
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity
Jesse Lai, Christine Hough, Julie Tarrant, et al.
Expert Review of Hematology
|
March 19, 2020
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms
David Lillicrap, Karin Fijnvandraat, Guy Young, et al.
Therapeutic Advances in Hematology
|
February 2, 2026
Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression
Sylvia Fong, Laura L Swystun, Paul Batty, et al.
Cellular Immunology
|
December 18, 2015
War and peace: Factor VIII and the adaptive immune response
Maria T Georgescu, Jesse D Lai, Christine Hough, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 11, 2022
Heterogeneity and reciprocity of FVIII and VWF expression, and the response to shear stress in cultured human endothelial cells
Christine Hough, Colleen Notley, Aomei Mo, et al.
Cellular Immunology
|
November 9, 2015
To clear or to fear: An innate perspective on factor VIII immunity
Jesse Derek Lai, Maria Teofana Georgescu, Christine Hough, et al.
American Journal of Obstetrics and Gynecology
|
December 26, 2002
A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period
Jennifer Oakes, Philip M Hahn, David Lillicrap, et al.
Thrombosis and Haemostasis
|
August 28, 2002
A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay
Bert Verbruggen, Waander van Heerde, Irena Novákovà, et al.
Journal of Molecular Modeling
|
August 24, 2004
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations
Jeffrey J Sutherland, Lee A O'Brien, David Lillicrap, et al.
Page
of 22
Search research articles
Search
Showing results (81-90 of 216) with videos related to
Sort By:
Page
of 22
Research and Practice in Thrombosis and Haemostasis
|
February 18, 2026
Factor VIII <i>in vitro</i> bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays
Jacob Lund, Mirella Ezban, Kasper Jensen, et al.
Blood
|
April 23, 2017
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity
Jesse Lai, Christine Hough, Julie Tarrant, et al.
Expert Review of Hematology
|
March 19, 2020
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms
David Lillicrap, Karin Fijnvandraat, Guy Young, et al.
Therapeutic Advances in Hematology
|
February 2, 2026
Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression
Sylvia Fong, Laura L Swystun, Paul Batty, et al.
Cellular Immunology
|
December 18, 2015
War and peace: Factor VIII and the adaptive immune response
Maria T Georgescu, Jesse D Lai, Christine Hough, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 11, 2022
Heterogeneity and reciprocity of FVIII and VWF expression, and the response to shear stress in cultured human endothelial cells
Christine Hough, Colleen Notley, Aomei Mo, et al.
Cellular Immunology
|
November 9, 2015
To clear or to fear: An innate perspective on factor VIII immunity
Jesse Derek Lai, Maria Teofana Georgescu, Christine Hough, et al.
American Journal of Obstetrics and Gynecology
|
December 26, 2002
A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period
Jennifer Oakes, Philip M Hahn, David Lillicrap, et al.
Thrombosis and Haemostasis
|
August 28, 2002
A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay
Bert Verbruggen, Waander van Heerde, Irena Novákovà, et al.
Journal of Molecular Modeling
|
August 24, 2004
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations
Jeffrey J Sutherland, Lee A O'Brien, David Lillicrap, et al.
Page
of 22